MIRM Stock Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mirum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.91 |
| 52 Week High | US$35.56 |
| 52 Week Low | US$23.76 |
| Beta | 1.14 |
| 1 Month Change | -7.97% |
| 3 Month Change | -9.23% |
| 1 Year Change | -8.09% |
| 3 Year Change | 28.34% |
| 5 Year Change | n/a |
| Change since IPO | 81.00% |
Recent News & Updates
Recent updates
Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?
Apr 22Mirum Pharmaceuticals Gets The 'Thumbs Up'
Dec 16Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Nov 25Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
Aug 24Analysts Have Made A Financial Statement On Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Second-Quarter Report
Aug 09Shareholder Returns
| MIRM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.7% | -4.2% | -3.7% |
| 1Y | -8.1% | -2.0% | 20.5% |
Return vs Industry: MIRM underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: MIRM underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| MIRM volatility | |
|---|---|
| MIRM Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MIRM's share price has been volatile over the past 3 months.
Volatility Over Time: MIRM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 264 | Chris Peetz | www.mirumpharma.com |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
Mirum Pharmaceuticals, Inc. Fundamentals Summary
| MIRM fundamental statistics | |
|---|---|
| Market cap | US$1.13b |
| Earnings (TTM) | -US$163.41m |
| Revenue (TTM) | US$186.37m |
6.0x
P/S Ratio-6.9x
P/E RatioIs MIRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIRM income statement (TTM) | |
|---|---|
| Revenue | US$186.37m |
| Cost of Revenue | US$47.04m |
| Gross Profit | US$139.34m |
| Other Expenses | US$302.75m |
| Earnings | -US$163.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.48 |
| Gross Margin | 74.76% |
| Net Profit Margin | -87.68% |
| Debt/Equity Ratio | 123.2% |
How did MIRM perform over the long term?
See historical performance and comparison